Pruritus
Conditions
Brief summary
Primary objective: * To compare the efficacy and safety profile of Fexofenadine 180mg tablets plus prednicarbate(2.5mg/g) vs prednicarbate(2.5mg/g) alone in the treatment of pruritic skin disease Secondary objective: * To evaluate patient's satisfaction of Allegra treatment
Interventions
DRUGFexofenadine
Sponsors
Handok Inc.
Study design
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
NONE
Eligibility
Sex/Gender
ALL
Age
12 Years to 70 Years
Healthy volunteers
No
Inclusion criteria
The following information on clinical trials is provided for information purposes only to allow patients and physicians to have an initial discussion about the trial. This information is not intended to be complete information about the trial, to contain all considerations that may be relevant to potential participation in the trial, or to replace the advice of a personal physician or health professional. Main criteria are listed hereafter: Inclusion Criteria: * All patients diagnosed with atopic dermatitis, contact dermatitis
Exclusion criteria
* Other skin disease except atopic dermatitis, contact dermatitis. * Subjects taken steroid within 4 weeks and antihistamine within 1 week before screening day. * Pruritus localized only head and face * Subjects with severe hepatic, renal, heart dysfunction. * Subjects with history of alcohol and drug abuse. * Pregnant and lactating women.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| The change of physician's assessment on pruritic score before and after 7-day treatment. | — |
Secondary
| Measure | Time frame |
|---|---|
| Patient visual analogue scale change and Overall satisfaction. | — |
Countries
South Korea
Outcome results
None listed